Open-label, Single Arm, Two-stage Study, Evaluating the Efficacy and Safety of Bimiralisib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (HNSCC) Harboring NOTCH1 Loss of Function (LOF) Mutations
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Bimiralisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HNSCC
- Sponsors PIQUR Therapeutics
- 09 Dec 2022 Results assessing the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant head and neck squamous cell carcinoma, published in the Oncologist.
- 09 Nov 2021 Status changed from completed to discontinued.
- 23 Feb 2021 Status changed from recruiting to completed.